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The coactivator PGC-1α1 is activated by exercise training in skeletal muscle and promotes
fatigue-resistance. In exercised muscle, PGC-1α1 enhances the expression of kynurenine
aminotransferases (Kats), which convert kynurenine into kynurenic acid. This reduces
kynurenine-associated neurotoxicity and generates glutamate as a byproduct. Here, we show
that PGC-1α1 elevates aspartate and glutamate levels and increases the expression of gly-
colysis and malate-aspartate shuttle (MAS) genes. These interconnected processes improve
energy utilization and transfer fuel-derived electrons to mitochondrial respiration. This PGC-
1α1-dependent mechanism allows trained muscle to use kynurenine metabolism to increase
the bioenergetic efﬁciency of glucose oxidation. Kat inhibition with carbidopa impairs
aspartate biosynthesis, mitochondrial respiration, and reduces exercise performance and
muscle force in mice. Our ﬁndings show that PGC-1α1 activates the MAS in skeletal muscle,
supported by kynurenine catabolism, as part of the adaptations to endurance exercise. This
crosstalk between kynurenine metabolism and the MAS may have important physiological
and clinical implications.
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The Pgc-1α gene encodes several transcriptional coactivatorproteins that coordinate the expression of gene networksinvolved in cellular adaptive processes1. Originally identi-
ﬁed as a single transcript and protein (PGC-1α12), Pgc-1α is now
known to encode several splice isoforms mostly involved in the
control of energy metabolism in several tissues3. One exception is
the PGC-1α4 variant, which regulates skeletal muscle mass4. In
skeletal muscle, PGC-1α1 is important for the adaptation to
aerobic exercise training as it ensures that fuel supply, oxygen
transport, and energy metabolism are coupled to increased
exercise performance and fatigue-resistance1. The connection
between PGC-1α1 and exercise performance has often been
attributed to the increase in muscle mitochondrial biogenesis and
fatty acid oxidation it mediates. This was ﬁrst observed in mice
with sustained PGC-1α1 expression in skeletal muscle (mck-
PGC-1α1 transgenics), which show many of the adaptations to
exercise without any training5. The elevation of Pgc-1α1 mRNA
expression in the mck-PGC-1α1 mice varies from oxidative to
glycolytic muscles between 2- and 10-fold, respectively. In
humans PGC-1α activation is achieved through endurance exer-
cise and its transcript can be elevated within the same range6,7.
Muscle resistance to fatigue during endurance exercise depends
on glycogen storage and its mobilization to glucose oxidation, as
well as on the capacity to oxidize fatty acids8. PGC-1α1 has been
shown to promote both glycogen storage and fatty acid oxida-
tion9–11. Maintaining glycolytic ﬂux depends (among other fac-
tors) on the renewal of the cytosolic NAD+ pool. This is
guaranteed by the transfer of glycolysis-generated NADH redu-
cing equivalents to lactate or into the electron transport chain (in
the latter case generating ATP). Since the inner membrane of the
mitochondria is not permeable to NADH, skeletal muscle uses a
glycerol-3-phosphate (G3P) shuttle (G3PS) that transports elec-
trons to Coenzyme Q, thus resulting in 1.5 ATP per NADH.
Other tissues such as the heart use the malate-aspartate shuttle
(MAS), where malate delivers NADH electrons to the mito-
chondrial complex I (yielding 2.25 ATP/NADH). The MAS
includes cytosolic and mitochondrial transamination reactions
that generate glutamate and aspartate (respectively), which are
then exchanged between compartments. These reactions are
catalyzed by glutamic-oxaloacetic transaminases 1 and 2 (Got1
and 2).
In addition to mitochondrial biogenesis and oxidative capacity,
there are other pathways regulated by PGC-1α1 that contribute to
muscle performance1. These include angiogenesis12,13 and neu-
romuscular communication14, among other. In addition, PGC-
1α1 regulates a muscle to brain crosstalk, activated by aerobic
exercise training, with a protective effect in the context of stress-
induced depression15. This mechanism relies on increasing the
expression of several kynurenine aminotransferases (Kats) in
muscle, that clear the neurotoxic tryptophan metabolite kynur-
enine (Kyn) from circulation, and prevent its accumulation in the
brain. Kyn accumulation in the CNS has been related to several
mental health disorders15–18. Muscle Kats convert Kyn into
kynurenic acid (Kyna)15, which in turn increases adipose tissue
energy expenditure and promotes an anti-inﬂammatory pheno-
type of the resident immune cells19. Both these biological activ-
ities of Kyna are mediated, at least in part, by GPR35 activation19.
Here we show that PGC-1α1 induces the expression of glyco-
lysis and MAS genes in skeletal muscle, thus increasing the energy
efﬁciency of glucose oxidation. In addition, we show that this
gene network includes both Kat and Got transaminases. This
allows trained muscle to use Kyn catabolism to support energy
production. Inhibition of Kat function, using gene silencing or
chemical inhibitors (such as carbidopa) reduce myotube oxidative
capacity and mouse exercise performance (respectively). Toge-
ther, our data provide an integrated mechanism that explains how
training can promote muscle neurotoxin detoxiﬁcation while
promoting adaptations to fatigue-resistance in the context of
endurance exercise.
Results and discussion
PGC-1α1 induces MAS genes in skeletal muscle. To discover
PGC-1α1-regulated hubs in skeletal muscle we used a multi-
omics data analysis approach. To this end, we analyzed muscle
transcriptomics data obtained from mck-PGC-1α1 mice (Sup-
plementary Data 1) together with metabolomics data reported for
another mouse model of chronic PGC-1α elevation in skeletal
muscle (HSA-PGC-1α-b)20 (Fig. 1a). The results of this analysis
suggested that PGC-1α1 positively regulates genes involved in the
biosynthesis and metabolism of aspartate in skeletal muscle
(Fig. 1b, c and Supplementary Fig. 1a). By quantifying the levels
of these metabolites, we could conﬁrm that aspartate and gluta-
mate are indeed elevated in skeletal muscle of mck-PGC-1α1
mice when compared to wild-type (wt) controls (Fig. 1d). The
same was observed in the muscle metabolomics data reported for
the HSA-PGC-1α-b mice20. Aspartate and glutamate are inti-
mately connected through glutamic-oxaloacetic transaminase 2
(GOT2). This transaminase is a crucial enzyme in aspartate
biosynthesis21,22 as it catalyzes the synthesis of aspartate from
oxaloacetate and glutamate (Fig. 1e). Interestingly, GOT2 is also
known as kynurenine aminotransferase 4 (KAT4), which we have
previously shown to be regulated by PGC-1α115. KAT enzymes
use kynurenine (Kyn) and α-ketoglutarate to generate kynurenic
acid (Kyna) and glutamate23,24 (Supplementary Fig. 1b). Skeletal
muscle PGC-1α1 increases the expression of Kat enzymes thereby
enhancing Kyn to Kyna conversion15. This has beneﬁts for
mental health in the context of stress-induced depression, as Kyn
accumulation in the CNS has neurotoxic effects17. In addition,
the elevation in circulating Kyna levels regulates adipose tissue
energy homeostasis19.
Muscle MAS gene clusters include Got and Kat transaminases.
Given that the reactions catalyzed by GOT2/KAT4 are involved
in metabolic pathways, such as aspartate biosynthesis and
kynurenine degradation21–24, we next aimed to determine whe-
ther all KAT enzymes share a speciﬁc biological function in
skeletal muscle. To this end, we used skeletal muscle expression
data from isogenic but diverse mouse strains (BXD type). We
then clustered Kat-associated gene modules by co-variation fol-
lowed by prediction of biological function by gene ontology
(Supplementary Fig. 2a, b). Interestingly, we observed that each
Kat gene cluster includes several genes involved in the regulation
of mitochondrial function and metabolism (Supplementary
Fig. 2c–e). Given this biological association, we next aimed to ﬁnd
overlapping molecular processes between the Kat-associated
networks. We then found that Kat1 and Got2/Kat4 strongly
associate with genes regulating the MAS (Fig. 1f, g). This asso-
ciation could also be observed in human skeletal muscle using
data that specializes in ﬁnding interacting genes that shape tissue-
speciﬁc functions25 (Supplementary Fig. 2f). Given that multi-
protein network interactions are crucial for several biological
processes across metazoans26, we then used a composition of
protein assemblies to conﬁrm multiprotein networks associated
with the Kat1-Got2/Kat4 and malate-aspartate cluster. This
revealed a conserved interacting protein network involved in
glycolysis and pyruvate metabolism (Supplementary Fig. 3).
The MAS is a biochemical shuttle used by the heart and liver to
transport glycolysis-derived electrons across the inner membrane
of the mitochondria for oxidative phosphorylation27 (Fig. 1k).
Skeletal muscle has been described to use a different, less efﬁcient
shuttle mediated by G3P27. Importantly, GOT2/KAT4, glutamate,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10712-0
2 NATURE COMMUNICATIONS |         (2019) 10:2767 | https://doi.org/10.1038/s41467-019-10712-0 | www.nature.com/naturecommunications
a b
c d e
f
i k
g h
mck-PGC-1α1 transcriptomics
30
–
lo
g 2
 
p-
va
lu
e
–
lo
g 2
 
p-
va
lu
e
R
el
at
ive
 le
ve
ls
log2 fold change log2 fold change
20
10
0
–4 –2 2 40
HSA-PGC-1α1 metabolomics
20
Integrated pathway analysis
Metabolite set enrichment analysis
Aspartate Glutamate
Glutamate
GFP Veh
PGC-1α1
GFP Kyn
PGC-1α1 Veh
Glucose
NAD+
α-KG α-KG
Mal
OAA
Asp
Mdh1
Got1
Mal
OAA
Asp
TCA
Mdh2
Got2
NADH
NAD+
NADH
NADH
NAD+
Lactate
Slc25a12
Slc25a11
Kat1 Got2 Kat3
Glu Glu
Pyruvate
KYN
KYNA
KYN
KYNA
Got2 = Kat4
Cytosol Mitochondrial matrixPGC-1α1 Kyn
PG
C-
1α
 
 
m
yo
tu
be
s
re
la
tiv
e
 le
ve
ls
Malate
Aspartate metabolism
Malate aspartate shuttle
2
1
0
40
50
30
En
ric
hm
en
t s
co
re
R
el
at
ive
 le
ve
ls
20
10
Mitochondrial respiratory chain complex III
Mitochondrial electron transport
Proton-transporting ATP synthase activity
Oxaloacetate metabolic process
Tricarboxylic acid cycle
Pyruvate metabolism
Aerobic respiration
Tricarboxylic acid cycle
NADH metabolic process
Citric acid cycle
Urea cycle
Glucose-alanine cycle
Protein biosynythesis
Arginine and proline metabolism
Nucleotide sugars metabolism
Thiamine metabolism
Purine metabolism
Mitochondrial electron transport chain
p -value
0 1 2
Fold enrichment
Atp5a1 Atp5o
Atpaf2Tfb1m
Ppara
S1c25a15
S1c25a13
Mdh2Ckmt2Ppargc1aAdck3Kat3
Ndufa10
Ndufa1 Esrra
Mdh1
Cyc1 Sdhaf2Ndufv1
Ndufb10Kat1
Got2/Kat4
3 4
0
WT
m
ck-
PG
C-1
α1 WT
m
ck-
PG
C-1
α1
WT
m
ck-
PG
C-1
α1
1
2
3
0
1
2
3 OAA
Asp
Got2
α-KG
Glu
4
M
yo
tu
be
s
re
la
tiv
e
 le
ve
ls
0
1
2
3
5
4
j Aspartate
KYN (μM) 0 1 10
1
2
3
4
5
4e
-01
4e
-03
Malate-aspartate shuttle
Aspartate and glutamate
metabolism
Pathway impact
14
12
10
8
6
4
2
0
–
lo
g 
p-
va
lu
e
15
5
10
0
–4 –2 2 40
Fig. 1 Regulatory hubs under PGC-1α1 control in skeletal muscle. a Transcriptomics and metabolomics analysis of mck-PGC-1α1 skeletal muscle.
b Integrated pathway analysis of mck-PGC-1α1 transcriptomics and metabolomics. c Metabolite enrichment analysis of mck-PGC-1α1. d Relative levels of
aspartate and glutamate in skeletal muscle of wt and mck-PGC-1α1 mice (n= 5). e Schematic representation of the role of GOT2 in aspartate synthesis.
f Overlapping Kat-associated networks. g Functional annotation of the Kat-associated network. h Relative levels of malate in skeletal muscle of wt and mck-
PGC-1α1 mice (n= 5). i Relative levels of glutamate in primary myotubes transduced with Gfp control or Pgc-1α1 adenovirus and supplemented with 1 μM
kynurenine (Kyn) (n= 4) j Relative levels of aspartate in primary myotubes transduced with Pgc-1α1 adenovirus treated with 0, 1 or 10 μM Kyn (n= 4).
k Schematic representation of how skeletal muscle PGC-1α1 integrates Kyn metabolism with aspartate biosynthesis and the malate-aspartate shuttle. Bars
depict mean values and error bars indicate SEM. Unpaired, two-tailed student’s t-test was used when two groups were compared, and one-way analysis of
variance (ANOVA) followed by Fisher’s least signiﬁcance difference (LSD) test for post hoc comparisons were used to compare multiple groups, *p < 0.05
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and aspartate are integral parts of the MAS. Within this shuttle,
aspartate exported from the mitochondrial matrix is used as the
precursor for malate, which in turn will be exchanged with α-
ketoglutarate through SLC25A11 (Fig. 1k). In line with this, we
found that the levels of malate are also increased in mck-PGC-
1α1 muscle (Fig. 1h), showing a strong correlation with the levels
of aspartate in skeletal muscle (r > 0.5) (Supplementary Fig. 4a).
In agreement with the higher levels of these metabolites, we
observed that skeletal muscle of mck-PGC-1α1 mice shows a
robust increase in the expression of genes coding for all the
constituents of the MAS (Supplementary Fig. 4b).
PGC-1α1 and Kyn increase glutamate and aspartate levels. To
test if these effects could be observed in a cell-autonomous
manner, we used primary myotube cultures with or without
ectopic Pgc-1α1 expression. We ﬁrst determined if, as suggested
by our bioinformatics analysis (Supplementary Fig. 3), PGC-1α1
would increase glycolytic ﬂux in cultured myotubes by using
cellular respirometry. Indeed, Pgc-1α1 expression in myotubes
increased ECAR levels at baseline, which were further increased
by the addition of glucose, and further by the inhibition of
mitochondrial respiration using oligomycin (Supplementary
Fig. 4c). ECAR values returned to baseline when 2-deoxyglucose
was added to inhibit glycolysis (Supplementary Fig. 4c). In
addition, we found that increasing Pgc-1α1 levels in myotubes is
sufﬁcient to increase glutamate levels (Fig. 1i) and the expression
of MAS genes (Supplementary Fig. 5a), thus placing PGC-1α1 as
a master regulator of the MAS in skeletal muscle. Surprisingly, we
found that Kyn supplementation to myotubes further increased
glutamate levels but only in the presence of Pgc-1α1 (Fig. 1i). In
agreement, treating PGC-1α1 myotubes with Kyn robustly ele-
vated aspartate levels (Fig. 1j). Under these conditions, Kyn and
PGC-1α1 induced the expression of MAS genes (Supplementary
Fig. 5a), of several transcription factors associated with PGC-1α1
function (Supplementary Fig. 5b), and of mitochondrial genes
(Supplementary Fig. 5c). As a consequence, supplementing Pgc-
1α1-transduced myotubes with Kyn further elevated cellular
respiration (Supplementary Fig. 5d, e). Importantly, Kyn-induced
basal respiration was completely abolished by the addition of the
ATP-synthase inhibitor oligomycin, indicating that the observed
increased in OCR is completely coupled to ATP production
(Supplementary Fig. 5e). These data indicate that PGC-1α1
confers myotubes with the ability to use Kyn to support the MAS,
mitochondrial respiration, and energy production (Fig. 1k).
PGC-1α1 reroutes Kyn catabolism to aspartate biosynthesis. To
conﬁrm the role of muscle PGC-1α1 in rerouting Kyn for MAS
support and energy production in vivo, we treated mck-PGC-1α1
mice with a single dose of Kyn. Again, we observed that Kyn was
able to elevate the expression of genes involved in energy meta-
bolism and MAS, but only in the mck-PGC-1α1 animals (Fig. 2a,
b and Supplementary Fig. 6a, b). The fact that at 1 μM Kyn does
not seem to have obvious effects on wt gastrocnemius (used in
these experiments) could indicate that the lower levels of PGC-
1α1 in these muscles (compared to more oxidative ones such as
the soleus) are limiting for the activation of the KAT/MAS
components (as previously suggested)15. Of note, transgenic
expression of Pgc-1α1 in the mck-PGC-1α mice, elevates overall
muscle PGC-1α1 to the levels observed in wt soleus5. Also at the
protein level, mck-PGC-1α1 mice showed increased expression of
MAS transporters (SLC25A11 and SLC25A12; Fig. 2c and Sup-
plementary Fig. 7). In agreement, skeletal muscle of mck-PGC-
1α1 mice had elevated levels of glutamate, aspartate, and malate,
which further increased with Kyn treatment (Fig. 2d). Although
the MAS transports NADH generated during glycolysis directly
into the mitochondrial matrix, we also observed an increase in
Pdha1 mRNA expression upon acute Kyn administration (Sup-
plementary Fig. 6b), which could be indicative of increased pyr-
uvate utilization. To assess if Kyn affects PDH protein levels and/
or activation we determined the p-PDH/PDH ratio by immu-
noblotting and no signiﬁcant difference was detected (Supple-
mentary Fig. 6c). These results indicate that activation of the
MAS by Kyn can increase ATP production by moving glycolysis-
derived NADH from the cytosol into the mitochondrial electron
transport chain, without changing pyruvate utilization.
PGC-1α deletion renders muscle susceptible to Kyn toxicity.
Using a mouse model with skeletal muscle-speciﬁc deletion of
Pgc-1α1 (MKO-PGC-1α14), we observed that these knockout
mice do not have the ability to use Kyn to support bioenergetics.
Indeed, MKO-PGC-1α muscle has reduced baseline levels of
genes involved in energy metabolism (including MAS genes),
which often got further reduced by Kyn administration (Fig. 2e
and Supplementary Fig. 6d–f). This was also translated into
reduced aspartate levels in skeletal muscle that did not change
after Kyn treatment (Fig. 2f). Interestingly, myotubes with genetic
deletion of Pgc-1α1 showed decreased respiration after Kyn
treatment (Fig. 2g and Supplementary Fig. 6g–h). Strikingly, Kyn
treatment reduced basal respiration to levels that were no longer
affected by oligomycin treatment (Fig. 2g), indicating that these
conditions lead to a severe compromise in ATP production.
Treating wt myotubes with high concentration of Kyn decreased
basal respiration (Fig. 2h and Supplementary Fig. 6i) and reduced
aspartate levels (Fig. 2i). This suggests that, above a physiological
threshold, Kyn-accumulation impairs aspartate biosynthesis
and mitochondrial respiration. However, myotubes transduced
with Pgc-1α1 can withstand the effect of Kyn accumulation (10
μM) on maximal respiration (Supplementary Fig. 6j). Since
muscle Kat expression is dependent on PGC-1α115, MKO-PGC-
1α and wt myotubes will have a reduced capacity to convert
Kyn into Kyna, thus allowing its degradation through the
kynurenine pathway (KP)17,18. Interestingly, KP metabolites such
as 3-hydroxykynurenine and 3-hydroxyanthranilic acid have been
shown to impair energy metabolism by direct inhibition of
mitochondrial respiration and ROS production28,29.
Contribution of MAS and fatty acids to myotube respiration.
Our results indicate that by allowing muscle to use Kyn and the
MAS, PGC-1α1 enhances energy production from glycolysis. In
agreement, Kyn supply to myotubes transduced with Pgc-1α1
further increased ATP levels (Fig. 3a). This was accompanied by
an elevation in the expression of glycolytic genes, which further
increased after Kyn treatment both in vitro and in vivo (Fig. 3b,
c). Although the mechanism for these PGC-1α1-dependent
effects of Kyn on glycolytic gene expression remains unknown,
it is tempting to speculate that Kyn to Kyna conversion could
regulate the expression or activity of a transcription factor yet to
be identiﬁed. To date, the only transcription factor known to be
activated by both Kyn and Kyna is the Aryl hydrocarbon receptor
(AHR), which has recently been shown to directly regulate gly-
colytic genes in type 1 regulatory T cells30. Activation of the MAS
in skeletal muscle could be in addition to or in replacement of the
G3PS26. Interestingly, PGC-1α1 does not inﬂuence the expression
of G3PS enzymes in vivo, in vitro or after Kyn treatment (Fig. 3d
and Supplementary Fig. 8a, b). To determine the functional
effects of inducing the MAS in skeletal muscle, we then inhibited
fatty acid oxidation by using a carnitine palmytoyltransferase-1b
(CPT1B) chemical inhibitor (Etomoxir). This reduced basal and
maximal respiration in wt myotubes by 64 and 75% (respec-
tively), whereas in myotubes overexpressing Pgc-1α1 the effect of
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Etoxomir was signiﬁcantly blunted (with a reduction of 35 % in
basal and 50 % maximal respiration; Fig. 3e). In fact, treating
myotubes overexpressing Pgc-1α1 with Etomoxir further
increased aspartate levels (Fig. 3f). Given that PGC-1α1 elevates
the expression of Cpt1b, we checked if this could affect the
experimental outcome but found no differences in its expression
after Etomoxir treatment (Supplementary Fig. 8c). This indicates
that myotubes overexpressing PGC-1α1 acquire the plasticity to
enhance glucose-malate-aspartate metabolism even when fatty
acid oxidation is reduced. To further assess the functional con-
tribution of the MAS in myotubes, we used the aminotransferase
inhibitor aminooxyacetate (AOA,100 μM), that works as a
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Fig. 2 PGC-1α1 reroutes kynurenine catabolism to support aspartate biosynthesis. a Relative transcript levels of mitochondrial related genes in skeletal
muscle of wt and mck-PGC-1α1 mice with a single intraperitoneal dose of kynurenine (Kyn, 2.5 mg/kg) (n= 4). b Relative transcript expression of genes
involved in malate-aspartate metabolism in skeletal muscle of wt and mck-PGC-1α1 mice treated as in a. c Protein levels of the malate-aspartate shuttle
constituents SLC25A11 and SLC25A12 in skeletal muscle of wt and mck-PGC-1α1 mice with a single intraperitoneal dose of Kyn. Uncropped western blots
are found as Supplementary Fig. 7. d Relative levels of glutamate, aspartate and malate in skeletal muscle of mck-PGC-1α1 mice treated as in a. e Relative
transcript levels of mitochondrial related genes in skeletal muscle of wt and MKO-PGC-1α mice with a single intraperitoneal dose of Kyn (n= 4). f Relative
levels of glutamate, aspartate and malate in skeletal muscle of wt and MKO-PGC-1α mice with a single intraperitoneal dose of Kyn (n= 4). g Extracellular
Flux Analysis (SeahorseTM) of cellular respiration in primary myotubes from MKO-PGC-1α supplemented with PBS (veh) or with 1 μM Kyn (n= 4).
h Percentage of basal oxygen consumption rate in primary myotubes supplemented with 1 and 10 μM of kynurenine (Kyn) (n= 4). i Relative levels of
aspartate in primary myotubes transduced with Pgc-1α1 adenovirus and treated as in h (n= 4). Bars depict mean values and error bars indicate SEM.
Unpaired, two-tailed student’s t-test was used when two groups were compared, and one-way analysis of variance (ANOVA) followed by Fisher’s least
signiﬁcance difference (LSD) test for post hoc comparisons were used to compare multiple groups, *p < 0.05
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chemical inhibitor of this shuttle31. Acute AOA treatment
reduced overall cellular respiration in myotubes (Fig. 3g) without
affecting ECAR (Supplementary Fig. 8e). In parallel, by using
transient siRNA transfections we reduced SLC25A12 and
SLC25A11 expression by 44 and 34%, respectively (Supplemen-
tary Fig. 8f). Under these conditions we did not observe any
effects on OCR, even when Kyn was added (Supplementary
Fig. 8g). Interestingly, Slc25a12 silencing elevated ECAR values at
baseline with little effect of Kyn addition, whereas Slc25a11
silencing had a more robust effect on ECAR values upon Kyn
addition (Supplementary Fig. 8h). In a similar fashion, Slc25a12
knockdown resulted in signiﬁcantly elevated aspartate levels that
were not affected by Kyn, whereas lowering Slc25a11 expression
had no effect (despite a trend towards elevated aspartate after
Kyn) (Supplementary Fig. 8i). Although the aspartate levels we
observed are within the range previously reported in human
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muscle32, the increase in aspartate we saw upon myotube
Slc25a12 silencing is in contrast with other studies33–35. This
could be due to the different levels of PGC-1α1 and Kat enzyme
expression in the different cells used (e.g. mouse myotubes vs
C2C12 myoblasts), as well as the presence of kynurenine and
other factors in the culture media.
Given the contribution of Kyn and KATs to support the MAS,
we next aimed to determine the individual functional effect of the
different KAT enzymes. We observed that silencing Kat1 and
Got2/Kat4 expression robustly decreased basal and maximal
respiration (Fig. 3h and Supplementary Fig. 8d), while increasing
ECAR (Supplementary Fig. 8j). As expected, aspartate levels were
reduced upon Got2/Kat4 silencing (Fig. 3i). Together, these data
indicate that interfering with the MAS at different points can have
different consequences such as decreased oxygen consumption,
increased glycolysis-derived lactate production, or both. This
interdependence on cytosolic and mitochondrial components is
not surprising. Indeed, it has been shown that whereas mck-PGC-
1α1 muscle is more efﬁcient than wt at using pyruvate, isolated
mitochondria from the same animals are not36.
Carbidopa reduces mouse exercise performance and strength.
We next evaluated the effects of Kat inhibition using carbidopa,
which irreversibly inactivates the Kat cofactor pyridoxal-5′-
phosphate (PLP)37. Interestingly, carbidopa is commonly used as
a dopamine decarboxylase inhibitor, which, in combination with
levodopa, represents a common therapy for pathologies such as
Parkinson’s disease and restless legs syndrome. However, since
carbidopa is only used in combination with levodopa, there are
limited reports addressing the effects of carbidopa alone on
peripheral tissues38. In line with our previous observations,
treating myotubes with carbidopa resulted in reduced maximal
respiration (Fig. 4a). To bypass the contribution of anaerobic
glycolysis, we incubated the myotubes with only pyruvate and
observed that carbidopa-mediated inhibition of respiration was
exacerbated in this condition (Fig. 4a). In fact, myotubes in
pyruvate that were treated with both carbidopa and Etomoxir
showed a drastic reduction in basal and maximal respiration
(Fig. 4a). Conﬁrming our previous observations (Fig. 3), these
effects were less pronounced in myotubes overexpressing Pgc-1α1
(Fig. 4a). Accordingly, carbidopa treatment in myotubes reduced
aspartate and malate levels (Fig. 4b), and the expression of genes
involved in energy metabolism (Supplementary Fig. 9a, b).
Interestingly, the effects of carbidopa on basal and maximal cel-
lular respiration could be partially rescued by aspartate treatment
(Fig. 4c).
To verify the impact of skeletal muscle Kat inhibition upon a
physiological-challenge, we evaluated the effects of sub-chronic
carbidopa administration in C57bl/6J mice using an exercise
performance test. We found that animals treated with
carbidopa run 30% less than controls in an exercise
performance test (Fig. 4d and Supplementary Fig. 9c) and
had reduced expression of genes involved in energy metabo-
lism in skeletal muscle (Supplementary Fig. 9d). Importantly,
the deleterious effects of carbidopa could be rescued by
aspartate treatment (Fig. 4d and Supplementary Fig. 9c). In
addition, using isolated ﬂexor digitorum brevis muscle, we
observed that carbidopa pre-treatment elicited a decrease in
relative contractile force, in a fatigue-induction protocol
(Fig. 4e). Interestingly, there are several heart and skeletal
muscle-related side effects and adverse reactions associated
with carbidopa38. Our observations suggest that the effects of
carbidopa on muscle metabolism could relate to some of these
adverse effects and that aspartate supplementation could have
clinical applications.
Finally, to determine if the MAS is part of the physiological
adaptation to exercise training, we analyzed malate and aspartate
metabolism in murine and human skeletal muscle after chronic
exercise interventions. We found that in mice, endurance exercise
training induces the expression of glycolysis and MAS-related
genes as well as malate and aspartate metabolite levels (Fig. 5a, b
and Supplementary Fig. 10a–c). Importantly, the effects of
exercise on MAS-related genes were lost in muscle-speciﬁc Pgc-
1α knockouts following both acute and chronic exercise
interventions (Fig. 5d and Supplementary Fig. 10d). The effects
of exercise training could also be observed in human skeletal
muscle (Fig. 5e, f and Supplementary Fig. 10e, f). Protein levels of
MAS components could also be found elevated by proteomics
analysis or trained vs untrained murine and human muscle
(Fig. 5c, g, respectively)39–42.
Conclusions
To date, at least three different mouse models of elevated Pgc-1α
expression in skeletal muscle have been reported, but not
always generated overlapping results (mck-PGC-1α15; PGC-1α
TRE (+)43; HSA-PGC-1α-b44). The three models use different
strategies to elevate PGC-1α in muscle. Mck- and HSA-driven
Pgc-1α expression is already activated at birth and remains on
during the life of the mice. These were the models used to gen-
erate the transcriptomics (this study) and metabolomics20 data,
respectively. Indeed, the metabolomics data obtained with the
HSA-PGC-1α-b mice, already highlighted the elevation in MAS
metabolites20. The PGC-1α TRE (+) model is an inducible model
(mice were kept on doxycycline which represses transgene
expression until it was removed from the diet, at about 5–6 weeks
of age). Evidence of differences between the models is reﬂected on
exercise performance, GLUT4 levels, glucose tolerance, insulin
sensitivity, among other. Importantly, PGC-1α TRE (+) mice
show a reduction in exercise capacity43, whereas the mck-PGC-1α
mouse has increased exercise performance45. Interestingly, both
models show increased muscle glycogen content at rest but the
mck-PGC-1α can use it during exercise46 whereas the PGC-1α
TRE (+) cannot43. Importantly, it has been shown that that
human type I skeletal muscle ﬁbers (rich in PGC-1α1) exhibit
higher levels of MAS enzymes, whereas type II ﬁbers have more
cGPDH47. In the same publication, the authors show that after
endurance training both ﬁber types have higher levels of MAS
enzymes.
Taken together, our results uncover a pathway regulated by
PGC-1α1 (Fig. 1k), which allows trained skeletal muscle to use
Kyn to support aspartate biosynthesis and mitochondrial func-
tion. These ﬁndings have implications on our understanding of
how aerobic training renders skeletal muscle resistant to fatigue,
by making glucose utilization more efﬁcient. This delays the
switch to fatty acid oxidation, a much more oxygen-demanding
process, which would precipitate reaching maximal aerobic
capacity. In addition, the observation that carbidopa inhibits this
process, and reduces the oxidative capacity of muscle, could have
important clinical implications38.
Methods
Animal experiments. Mck-PGC-1α1 and MKO-PGC-1α animals (all on C57bl/6J
background), a kind gift from Dr. Bruce Spiegelman (Harvard Medical School,
Boston, MA), have been previously described5,13. Wild-type mice (C57bl/6J) were
procured from Janvier Labs (France). Mice were housed in plastic cages (3–5 per
cage) at 24 ± 1 °C, 12/12 h controlled light conditions with ad libitum access to
water and food. All mice were male and 10–14 weeks of age. All experiments were
approved by the regional animal ethics Committee of Northern Stockholm, Sweden
or of Basel-Stadt, Switzerland.
Chemical treatments. Differentiated myotubes were treated for 4 h with L-
Kynurenine (Kyn) sulfate salt (Sigma-Aldrich; 1 μM). When stated, differentiated
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myotubes were treated with different concentrations of Kyn (1 and 10 μM) for 4 h.
C57bl/6J, mck-PGC-1α1 and MKO-PGC-1α mice received intraperitoneal injec-
tions of Kyn (2.5 mg/Kg) or PBS 3–4 h before sacriﬁce.
Differentiated myotubes were treated for 24 h with L-carbidopa (CBP) (Sigma-
Aldrich; 40 μM). When stated, myotubes where supplemented after CBP treatment
with L-Aspartate (Sigma-Aldrich; 100 μM) 1 h before cell collection or Extracellular
ﬂux analysis assay. C57bl/6J mice received CBP (25 mg/Kg) or PBS
intraperitoneally once per day for 4 days. When stated, L-Aspartate (12.5 mg/Kg)
was intraperitoneally injected alone or together with CBP injections for 4 days.
Differentiated myotubes were treated for 1 h with Etomoxir (Sigma-Aldrich;
50 μM). When stated, myotubes where supplemented, after CBP treatment, with
Etomoxir 1 h before cell collection or Extracellular ﬂux analysis assay.
Aminooxyacetate (AOA) was used at 100 μM for 1 h before measurement.
Differentiated myotubes were transfected using Lipofectamine RNAMax (Life
Technologies) with 25 nM of siRNA for Kat1 (Thermo Fisher Scientiﬁc siRNA ID #
181312; AGU AGU AGC UUG GAC GAA A), siRNA for Kat3 (Thermo Fisher
Scientiﬁc siRNA ID # 171263; GCC CUA CUU CAC CUG AUC G), siRNA for
Kat4 (Thermo Fisher Scientiﬁc siRNA ID # 158792; CAA UAG CGA UGA UAC
UGG G), siRNA for Slc25a11 (Dharmacon siRNA ID # 67863; UGG CCG GAU
GGA CGG GAA A; GGA CUA GUG UGC CAG GCU U; AAA CUA GGA UCC
AGA AUA A; AGU UAG GAU UGC CAG GGA A), siRNA for Slc25a12
(Dharmacon siRNA ID # 78830; GCU CCA AGA UUG CGA GAA A; GAU ACA
AGG CAG AGC GAA A; GUU UAA GUC UCC UAG CGU A; ACA UGG AGC
UUG UUC GAA A) or a scrambled control (Life Technologies).
Extracellular ﬂux analysis (Seahorse®) assays. Cells were differentiated and
treated as described above. On the 4th day of differentiation, mitochondrial oxi-
dative phosphorylation from mouse differentiated myotubes was analyzed using
extracellular ﬂux analysis (XF24; Seahorse Biosciences) in DMEMmedium (pH 7.4;
Sigma-Aldrich). Unless otherwise stated, the Mitochondrial Stress Test assay was
performed with 1 mM pyruvate and 25 mM glucose (Sigma-Aldrich). Baseline
oxygen consumption rates (OCR) and extracellular acidiﬁcation rate (ECAR) were
measured every 7th minute. Following baseline measurements, oligomycin (1 μM),
Carbonyl cyanide-4 (triﬂuoromethoxy)phenylhydrazone (FCCP) (1 μM), and
antimycin A (2 μM) were sequentially injected to measure OCR and ECAR. The
glycolytic ﬂux was measured using the Glycolytic Stress Test assay performed in
DMEM medium (pH 7.4; Sigma-Aldrich). Baseline ECAR was measured every 7th
minute. Following baseline measurements, glucose (10 mM), oligomycin (1 μM),
and 2-deoxyglucose (100 mM) were sequentially injected followed by ECAR
measurements.
Analysis of gene expression. Total RNA was isolated from cells or tissues using
Isol-RNA Lysis Reagent (5 PRIME) according to manufacturer’s instructions.
One microgram of RNA was treated with Ampliﬁcation Grade DNase I (Life
Technologies) and from that, 500 ng of total RNA were used for cDNA pre-
paration using the Applied Biosystem Reverse Transcription Kit (Life Technol-
ogies). Quantitative Real-Time PCR was performed in a ViiA 7 Real-Time PCR
system thermal cycler with SYBR Green PCR Master Mix (both Applied Bio-
systems). Analysis of gene expression was performed using the ΔΔCt method and
relative gene expression was normalized to hypoxanthine phosphoribosyl-
transferase (Hprt) mRNA levels. Gene expression analyses were expressed as
mRNA levels relative to controls. Primer sequences are found in Supplementary
Data 2.
Primary cell culture. Primary mouse myoblasts were isolated from 2-weeks-old
C57bl/6J or MKO-PGC-1α mice as previously described4. In brief, mouse hin-
dlimb muscles were dissected out and digested to a homogenate in a collagenase/
dispase solution (2.4 U/mL Dispase (Grade II) (Roche 295825); 1% Collagenase
B (Roche 1088815); 2.5 mM CaCl2; in MilliQ water). Myoblasts were cultured in
collagen-coated plates and maintained in Ham’s F-10/DMEM media mixture
(Thermo Fisher Scientiﬁc) supplemented with 20% FBS (Sigma-Aldrich), 1%
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penicillin/streptomycin (Thermo Fisher Scientiﬁc), and 2.5 ng/mL basic ﬁbro-
blast growth factor (Thermo Fisher Scientiﬁc). To induce differentiation into
myotubes, cells were shifted to DMEM high glucose with pyruvate (Thermo
Fisher Scientiﬁc) media supplemented with 5% horse serum (Thermo Fisher
Scientiﬁc) and 1% penicillin/streptomycin (Thermo Fisher Scientiﬁc). When
stated, 48 h after induction of differentiation, cells were transduced with an
adenovirus to induce Pgc-1α1 expression or a control adenovirus. Twelve hours
after transduction medium was replaced with fresh differentiation medium and
approximately 48 h post-transduction, cells were harvested.
Adenovirus-mediated expression. Adenovirus expressing Gfp and Pgc-1α1 were
generated by using the pAdTrack/pAdEasy system (Stratagene). For cell culture
experiments, differentiated myotubes were transduced with an adenovirus at an
MOI of 100 for 12 h. Cells were harvested 2 days after transduction.
Western blot. Cell or tissues lysates were obtained using RIPA buffer (50 mM tris
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (w/v) Triton-X-100, 0.5% (w/v) Na-
deoxycholate, 0.1% (w/v) sodium dodecyl sulfate, 20 mM glycerol-2-phosphate,
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5 mM sodium pyrophosphate) freshly supplemented with 1 mM DTT and 0.5 mM
PMSF. Each protein extract was resolved by SDS polyacrylamide gel membranes
(PAGE), and blots were incubated with the monoclonal antibodies anti-PDH-E1α
(9H9AF5; Thermo Fisher Scientiﬁc) or anti-Slc25a12 (kind gift of Dr. Jorgina
Satrústegui), or the polyclonal antibodies anti-phosphoPDH-E1α Ser290 (AP1062;
Calbiochem) or anti-Slc25a11 (AB80464; Abcam). Samples were normalized using
monoclonal antibody anti-α-tubulin (T6199; Sigma-Aldrich). All antibodies were
used at 1:1000, except anti-Slc25a12 that was used at 1:5000.
Uncropped and unprocessed scans of the westerns shown in Fig. 2c are found in
Supplementary Fig. 7.
Human endurance exercise. Skeletal muscle biopsies from two groups of young
adult male subjects were used. The ﬁrst group (n= 9) was pursuing endurance
training for a 150-km road cycling time trial (11.8 ± 4.8 training hours per week),
and the second group (n= 8) was recreationally active but not speciﬁcally parti-
cipating in endurance training. Skeletal muscle biopsies were taken 12 h after
exercise completion from m. vastus lateralis under local anesthesia using the
Pajunk DeltaCut system (Pajunk, Geisingen, Germany). Approximately 40 mg of
muscle tissue was collected in the rested conditions for each subject, snap frozen in
liquid nitrogen, and stored at −80 °C until further analysis. The study was
approved by the regional ethics committee and each subject provided written
informed consent before participation.
Free wheel running. Nine-week-old C57bl/6J male mice were single-housed and
divided into two groups: control and exercise. After an acclimation period of
5–6 days, the exercised group was given access to a running wheel with a counter
that monitored revolutions during 8 weeks. Control group mice were housed in
similar cages without running wheels. Only animals that had run more than 4 km/
night were selected for subsequent experiments. Gastrocnemius muscles were
collected at 12 hours after the last bout of exercise.
Exercise performance. Treadmill runners (n= 6) followed an acclimation pro-
tocol (day 1 running 5 m/min for 10 min; day 2 running 5 m/min for 10 min
followed by 10 m/min for 5 min; day 3 running 5 m/min for 10 min followed by 10
m/min for 5 min and 15 m/min for 2 min). After acclimation, mice were placed on
a motorized treadmill (Columbus Instruments, USA), with a slope of 5° and
warmed-up for 5 min at 5 m/min. The speed was increased (2 m/min every 2 min)
up to 35 m/min. Speeds varied between 10 and 25 m/min during the experiment to
allow mice to keep up with the protocol. Mice ran for 1 h or until exhaustion. We
considered exhaustion as the total incapacity to keep up with the running pace even
when the speed was lowered to 15 m/min. Gastrocnemius muscles were collected
12 h after the running to exhaustion protocol was performed.
Acute and chronic exercise. Prior to the long endurance exercise exhaustion test
or chronic exercise training, MKO-PGC-1α or wild-type littermate control mice
were familiarized with treadmill running. The exhaustion test was performed at an
inclination of 5° and started at 5 m/min for 5 min followed by 5 min at 8 m/min.
Subsequently, velocity was increased by 2 m/min every 15 min until mice reached
exhaustion (criteria described above). Mice were sacriﬁced 6 hours post-exhaustion
and quadriceps muscles were removed and snap frozen in liquid nitrogen. Chronic
exercise training was performed on a motorized treadmill for 4 weeks. Mice were
trained 5 days/week for 1 h, progressively increasing the velocity throughout the
training period (inclination of 5°). 18 hours after the last training session, mice
were sacriﬁced and quadriceps muscles was removed and snap frozen in liquid
nitrogen.
Muscle tissue from these exercise studies was homogenized in 1 mL TRIzol
Reagent (Thermo Fisher Scientiﬁc) using FastPrep lysing matrix tubes (MP
Biomedicals). RNA was isolated with the TRIzol extraction method and performed
according to the manufacturer’s protocol. One µg RNA was treated with
Ampliﬁcation Grade DNase I (Life Technologies) and reverse transcribed using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Quantitative Real-Time PCR was performed on the QuantStudio 5 using Fast
SYBR Green PCR Master Mix (both Applied Biosystems).
Skeletal muscle force and fatigue measurement. The ﬂexor digitorum brevis
(FDB) muscles from both hind paws of C57bl/6J mice after CBP or PBS injection
were quickly excised under the microscope after the sacriﬁce. During the excision
procedure and force measurements, the muscles were kept in a Tyrode solution
containing (in mmol/L): 121 NaCl, 5 KCl, 1.8 CaCl2, 0.4 NaH2PO4, 0.5 MgCl2, 24
NaHCO3, 0.1 EDTA, and 5.5 glucose. The Tyrode solution was gassed with 95%
O2‐5% CO2, giving a bath pH of 7.4. The proximal and distal tendons of FDB
muscles were tied with nylon thread. Muscles were mounted between a force
transducer and an adjustable holder (World Precision Instruments) in a 15 mL
stimulation chamber. The chamber temperature was set at 31 °C with a water‐
jacketed circulation bath and the muscles were bathed in the Tyrode solution
continuously gassed with 95% O2‐5% CO2. Muscles were stimulated with supra-
maximal current pulses (0.5 msec duration; 150% of current required for max-
imum force response) via plate electrodes lying parallel to the muscles. Muscles
were set to the length at which tetanic force was maximum (optimal length L0) and
were then allowed to recover for 15 min. L0 was measured with a caliper and
recorded. FDB muscles underwent a fatigue protocol consisting of 50 tetanic
contractions (70 Hz, 300 ms train duration, 2 s interval duration). Electrically sti-
mulated force production was expressed as speciﬁc force (kN/m2). Muscle cross‐
sectional area (CSA) was assessed by dividing muscle mass by the product of
muscle length and muscle density (1.06 g/cm3). The muscle mass was determined
after the experiments by cutting the major part of the tendons.
Kit measurements. Aspartate, Malate, and Glutamate quantiﬁcation from mouse
skeletal muscle samples were done using a commercially available kit (Abcam
ab102512, ab83391, and ab138883, respectively), following manufacturer’s
instructions.
Transcriptomic and metabolomic analysis. We analyzed muscle transcriptomics
(Supplementary Data 1) and metabolomics20 data obtained from skeletal muscle of
mck-PGC-1α1 mice. Metabolite set enrichment analysis was performed using the R
package MetaboAnalystR48,49. Integrated metabolic pathway analysis of tran-
scriptomic and metabolomics data was performed using the same R package.
Proteomics analysis. We analyzed publicly available data from muscle proteomics
from murine39 and from humans40–42 obtained from skeletal muscle after exercise
training.
KAT-associated network. To assess the KATs-associated network in murine
skeletal muscle, we used RNAseq data from isogenic BDX mice (archived in http://
www.GeneNetwork.org)50. Person’s r correlations for Kat1, Kat3 and Got2/Kat4 in
wild-type skeletal muscle were calculated (>0,4, p < 0,05) followed by DAVID
functional clustering analysis51 in each independent network and in overlapping
networks. To assess the KATs-associated network in human skeletal muscle we
performed Kats-targeted approach of overlapping networks using a tissue-
integrated genome-scale analysis (archived in http://giant.princeton.edu)25. This
was followed by DAVID functional clustering.
To evaluate interacting protein-networks for the functional units of the malate-
aspartate shuttle we used data from soluble protein-protein-interaction complexes
evaluated across diverse metazoan models (data stored in http://metazoa.med.
utoronto.ca)
Statistical analysis. Data is expressed as average+ SEM. For in vitro experiments,
n indicates independent experiments with at least three technical replicates. The
number of biological replicates used was based on our previous experience with the
different protocols used. For in vivo experiments, n indicates number of mice per
group. The number of animals used in each experiment was counted accordingly
with our previous experience and standards within the ﬁeld. This is the minimal
number of mice needed to achieve statistical signiﬁcance for most of the tests
performed. All subjects (control and test) were randomized according to age,
gender and weight. All statistical analyses (including outliers test) were performed
using GraphPad Prism 6. Unpaired student’s t-test was used when two groups were
compared, and one-way analysis of variance (ANOVA) followed by Fisher’s least
signiﬁcance difference (LSD) test for post hoc comparisons was used to compare
multiple groups. Statistical signiﬁcance was deﬁned as p < 0.05. Correlations were
calculated by Pearson correlation.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Authors can conﬁrm that all relevant data are included in the paper and/or its
supplementary information ﬁles.
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